Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence?

CNS Drugs

Volumn 16, Issue 2, 2002, Pages 77-89

  Henderson, David C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Freedom Trail Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGE DISTRIBUTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC KETOACIDOSIS; DISEASE EXACERBATION; DRUG POTENCY; DRUG WITHDRAWAL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SCREENING TEST; WEIGHT GAIN;

EID: 0036180024     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216020-00001     Document Type: Review

References (106)

1. Persistent tardive dyskinesia and neurolpetic effects on glucose tolerance
2. Blood sugar levels in patients treated with chlorpromazine
3. Delayed action of insulin in schizophrenia
4. A survey of unknown diabetes in a mental hospital: I
5. A survey of unknown diabetics in a mental hospital: II. Men from age fifty
6. Diabetes in chronic schizophrenia
7. Plasma free fatty acids before and after an intravenous insulin injection in acute schizophrenic men
8. The positive correlation between insulin resistance and duration of hospitalization in untreated schizophrenia
9. Glucose-insulin metabolism in chronic schizophrenia
10. A study of relationships of serum glucose, insulin, free fatty acids, and free and total tryptophan to mental illness
11. Diabetes mellitus in schizophrenic patients
12. Diabetes and schizophrenia - A preliminary study
13. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Third National Health and Nutrition Examination Survey, 1988-1994
14. Nonketotic hyperglycemia associated with loxapine and amoxapine: Case report
15. Phenothiazines and diabetes in hospitalized woman
16. Psychotropic drugs, diabetes and chronic mental patients
17. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
18. Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients
19. Clozapine reduces violence and persistent aggression in schizophrenia
20. A fatal drug interaction between clozapine and fluoxetine
21. The effects of clozapine on aggression and substance abuse in schizophrenic patients
22. Clozapine associated reduction in arrest rates of psychotic patients with criminal histories
23. Excess mortality of mental disorder
24. Mortality in current and former users of clozapine
25. Diabetic ketoacidosis associated with clozapine treatment
26. Ketoacidosis as a side-effect of clozapine: A case report
27. Diabetic ketoacidosis from clozapine and lithium cotreatment
28. Clozapine-induced diabetic ketoacidosis
29. Diabetic ketoacidosis associated with clozapine treatment
30. Schizophrenia and diabetes mellitus
31. Diabetic ketoacidosis and clozapine
32. Severe hyperglycemia associated with high doses of clozapine
33. Clozapine and associated diabetes mellitus
34. Novel antipsychotics and new onset diabetes
35. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
36. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
37. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
38. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
39. Expert committee on the diagnosis and classification of diabetes mellitus
40. Serum triglycericle levels in patients treated with clozapine
41. Clozapine and weight gain
42. Differential effect of clozapine on weight: A controlled study
43. Weight gain among schizophrenic patients treated with clozapine
44. Weight gain associated with clozapine
45. Drug-produced obesity: Experiences with chlorpromazine, perphenazine, and clopenthixol
46. Insulin resistance versus insulin secretion in the hypertension of obesity
47. Weight gain among patients on clozapine
48. Weight gain associated with psychotropic drugs
49. The effects of antipsychotic drugs on body weight: A retrospective review
50. Weight gain associated with neuroleptic medication: A review
51. Clozapine-induced weight gain
52. A comparison of sustained-release bupropion and placebo for smoking cessation
53. Efficacy of olanzapine: An overview of pivotal clinical trials
54. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
55. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy
56. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy
57. Hyperglycemia and ketoacidosis associated with olanzapine
58. Olanzapine-induced ketoacidosis with diabetes mellitus
59. Hyperglycemia associated with olanzapine
60. Diabetic ketoacidosis with olanzapine treatment
61. Hyperglycemia in schizophrenic patients treated with olanzapine and clozapine
62. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
63. Olanzapine-induced elevation of plasma triglyceride levels
64. Olanzapine increases weight and serum triglyceride levels
65. Cardiovascular risk in diabetes: A brief review
66. Weight changes in patients treated with quetiapine
67. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
68. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
69. New onset diabetes and ketoacidosis with atypical antipsychotic agents
70. Olanzapine-induced glucose dysregutation
71. New-onset diabetes mellitus associated with quetiapine
72. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control
73. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials
74. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone
75. Phase-IV multicentre clinical study of rsiperidone in the treatment of outpatients with schizophrenia
76. Risperidone-associated diabetes hyperprolactinemia
77. Diabetic ketoacidosis associated with risperidone treatment?
78. The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells
79. Reply to Drs. Haupt and Newcomer
80. Risperidone-associated new-onset diabetes
81. Abnormalities in glucose regulation during antipsychotic treatment in schizophrenia
82. Atypical antipsychotic-induced differences in glucose regulation in schizophrenia independent of differences in adiposity
83. Glucose metabolism during antipsychotic treatment in schizophrenia
84. Risperidone treatment for a patient suffering from schizophrenia and IDDM
85. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in II geriatric patients: A case series
86. Antipsychotic induced weight gain: A comprehensive research synthesis
87. Insulin resistance in olanzapineand ziprasidone-treated patients: Interim results of a double-blind controlled 6-week trial
88. Diabetic ketoacidosis with clozapine treatment
89. Atypical antipsychotics: Impaired glucose metabolism
90. Insulin sensitivity, insulin secretion, and glucose effectiveness in subjects with impaired glucose tolerance: A minimal model analysis
91. Obesity, non-insulin-dependent diabetes mellitus and the metabolic syndrome
92. Atypical antipsychotic agents and glucose metabolism: Bergman's Minimal Model analysis
93. Toward an integrated phenotype in pre-NIDDM
94. Lilly lecture 1989. Toward physiological understanding of glucose tolerance
95. Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC 12) cells
96. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells
97. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics
98. Medical hazards of obesity
99. Metabolic studies in unaffected co-twins of non-insulin-dependent diabetics
100. Kelly West lecture 1991. Challenges in diabetes epidemiology - From West to the rest
101. Diabetic ketoacidosis in patients with schizophrenia disorders
102. Association of new-onset diabetes and antipsychotics: Findings from a large health plan database
103. Prevalence of diabetes in schizophrenia patients treated with antipsychotic agents
104. Hyperglycemia in schizophrenic patients treated with olanzapine and clozapine
105. Diabetes mellitus with atypical neuroleptics